International journal of laboratory hematology最新文献_第3页

Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non-Hodgkin Large B-Cell Lymphoma: A Comparative Study of Cell-Free DNA and Formalin-Fixed Paraffin-Embedded Tissue.

International journal of laboratory hematology Pub Date : 2025-02-27 DOI: 10.1111/ijlh.14454

Gayaththri Vimalathas, Oriane Cédile, Marie Louise Grube Kjeldsen, Mads Thomassen, Michael Boe Møller, Charlotte Guldborg Nyvold, Marcus Høy Hansen, Thomas Stauffer Larsen

{"title":"Liquid Biopsy for Enhanced Specificity in Identifying Somatic Mutations in Aggressive Non-Hodgkin Large B-Cell Lymphoma: A Comparative Study of Cell-Free DNA and Formalin-Fixed Paraffin-Embedded Tissue.","authors":"Gayaththri Vimalathas, Oriane Cédile, Marie Louise Grube Kjeldsen, Mads Thomassen, Michael Boe Møller, Charlotte Guldborg Nyvold, Marcus Høy Hansen, Thomas Stauffer Larsen","doi":"10.1111/ijlh.14454","DOIUrl":"https://doi.org/10.1111/ijlh.14454","url":null,"abstract":"Introduction: Formalin-fixed paraffin-embedded (FFPE) tumor biopsy is the current mainstay of genotyping, but is limited by its invasiveness and tumor heterogeneity. Plasma cell-free DNA (cfDNA) constitutes a minimally invasive alternative that may better capture tumor-derived profiles from circulating tumor DNA (ctDNA). This study compares the performance and genomic concordance of cfDNA and FFPE tumor DNA in aggressive non-Hodgkin large B-cell lymphoma.Methods: Paired diagnostic FFPE tissue and plasma samples from 15 patients were sequenced with a custom 53-gene panel.Results: Detection thresholds were empirically guided at 1% variant allele frequency (VAF) for cfDNA and 10% for unpaired FFPE DNA. The median number of cfDNA variants was 6 (interquartile range (IQR): 2-11) versus 63 (IQR: 15-250) in FFPE DNA at 1% VAF. Collectively, 102 somatic variants were shared between cfDNA and FFPE DNA with a median of 5 (range: 0-23). cfDNA showed a five-fold lower median VAF for shared variants than FFPE DNA (7% vs. 36%, p < 0.0001). Eighty percent of patients harbored at least one cfDNA variant. A maximum cfDNA recall rate of 83% was observed at FFPE DNA VAF > 50%. COSMIC database overlap was twice as high for cfDNA compared to FFPE DNA (22% vs. 11%) at 10% VAF.Conclusion: cfDNA has superior specificity for somatic mutation detection but lower sensitivity than FFPE DNA. Modest concordance was demonstrated between the two compartments. Our results support a complementary role of ctDNA in mutational profiling at a 1% VAF threshold in a pragmatic and clinically applicable setup.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How I Investigate Measurable Residual Disease in B-Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi-Specific Monoclonal Antibodies and 19CAR-T Cells.

International journal of laboratory hematology Pub Date : 2025-02-26 DOI: 10.1111/ijlh.14448

Maura Rosane Valerio Ikoma-Colturato, Felipe Magalhães Furtado, Elen de Oliveira, Fabiola Gevert, Roberia Mendonça

{"title":"How I Investigate Measurable Residual Disease in B-Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi-Specific Monoclonal Antibodies and 19CAR-T Cells.","authors":"Maura Rosane Valerio Ikoma-Colturato, Felipe Magalhães Furtado, Elen de Oliveira, Fabiola Gevert, Roberia Mendonça","doi":"10.1111/ijlh.14448","DOIUrl":"https://doi.org/10.1111/ijlh.14448","url":null,"abstract":"Introduction: Measurable residual disease (MRD) in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) following anti-CD19 targeted therapies requires specific strategies to identify residual blast cells due to loss or reduced CD19 expression that makes it inconsistent as a primitive marker for B-cell gating.Objective: Due to the increased access of BCP-ALL patients to therapies with CD3/CD19 bispecific T-cell engagers (BiTe) and CD19-targeted chimeric antigen receptor T-Cell (CAR-T), it is essential that flow cytometry laboratories are prepared to evaluate therapeutic responses.Material and methods: Here, validated strategies for MRD detection in the context of anti-CD19 therapies are described, accessible to flow cytometry laboratories according to their different facilities. The paper includes an 8-color flow cytometry (FC) strategy for BCP-ALL MRD based on alternative gating without the use of additional markers (Euroflow protocol), as well as other strategies using alternative markers to CD19, comprising 2 protocols using 8 colors, one using 10 colors and another 14 colors/15 markers.Conclusion: Different strategies are needed to detect MRD without using CD19 for B-cell population gating after CD19-targeted therapies. However, it is essential that validated protocols are used according to the available resources to ensure reliable results for clinical decision-making.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic Diversity in KMT2A-r and KMT2A-Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants.

International journal of laboratory hematology Pub Date : 2025-02-25 DOI: 10.1111/ijlh.14442

Karina Ilyasova, Elena Zerkalenkova, Olga Soldatkina, Anna Kazakova, Natalya Myakova, Julia Roumiantseva, Veronica Fomynih, Alexander Popov, Grigory Tsaur, Yulia Olshanskaya, Michael Maschan

{"title":"Genetic Diversity in KMT2A-r and KMT2A-Wt Groups: Assessing the Prognostic Value of Markers in BCP-ALL Among Infants.","authors":"Karina Ilyasova, Elena Zerkalenkova, Olga Soldatkina, Anna Kazakova, Natalya Myakova, Julia Roumiantseva, Veronica Fomynih, Alexander Popov, Grigory Tsaur, Yulia Olshanskaya, Michael Maschan","doi":"10.1111/ijlh.14442","DOIUrl":"https://doi.org/10.1111/ijlh.14442","url":null,"abstract":"Background/objectives: Infant BCP-ALL is classified into KMT2A-r and KMT2A-wt groups, both showing heterogeneity. KMT2A rearrangements indicate poor prognosis, but outcomes vary by fusion partner. The KMT2A-wt group includes cases in the B-other ALL subgroup, with unclear prognostic significance. We aim to improve understanding of molecular subtypes in KMT2A-r and KMT2A-wt, focusing on NUTM1 and PAX5 rearrangements.Methods: We analyzed 175 infants (aged 0-365 days) diagnosed with BCP-ALL from 2010 to 2023 at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Genomic aberrations were identified by karyotyping, FISH and RNA-seq. RNA-seq was performed using the Illumina, and gene fusions were validated by Sanger sequencing.Results: There was no difference in survival based on KMT2A partner genes. The KMT2A::AFF1 group showed similar outcomes to other partners, with 2-year EFS of 36% (95% CI, 21%-59%) versus 37% (95% CI, 23%-60%) (log-rank test, p = 0.9). In the KMT2A-wt group (n = 33, 17.7% of cases), NUTM1-r (n = 9) and PAX5-r (n = 10) accounted for 27% and 30.3%, respectively. The NUTM1-r and PAX5-r groups showed excellent survival rates, with 2-year EFS of 80% (95% CI, 52%-100%) and 100% (95% CI, 100%-100%), respectively, but the small cohort size limit the statistical power of the analysis (log-rank test, p = 0.9).Conclusions: Survival in the KMT2A-r group did not differ by fusion partner. NUTM1 rearrangements showed a favorable prognosis, and PAX5-rearranged patients had better outcomes than previously reported. In the NUTM1-r group, the most common fusion, BRD9:NUTM1, showed variability in breakpoints (Exons 3, 8, and 14 of BRD9).","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Chemoimmunotherapy. lncRNA HOTAIR和MALAT1的过表达与lncRNA PANDA的低表达可预测弥漫大B细胞淋巴瘤对R-CHOP化学免疫疗法的耐受性

International journal of laboratory hematology Pub Date : 2025-02-25 DOI: 10.1111/ijlh.14440

Yara Mohamed Ahmed, Nashwa El-Khazragy, Riham Abdel-Hamid Haroun, Shadia Abdel-Hamid Fathy

{"title":"Overexpression of lncRNAs HOTAIR and MALAT1 While Downexpression of lncRNA PANDA Predict the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Chemoimmunotherapy.","authors":"Yara Mohamed Ahmed, Nashwa El-Khazragy, Riham Abdel-Hamid Haroun, Shadia Abdel-Hamid Fathy","doi":"10.1111/ijlh.14440","DOIUrl":"https://doi.org/10.1111/ijlh.14440","url":null,"abstract":"Background: Long noncoding RNAs (lncRNAs) have emerged as key regulators of cancer; in addition, they have been identified as novel therapeutic targets and biomarkers for several cancers, including diffuse large B-cell lymphoma (DLBCL).Methods: A total of 75 DLBCL patients and 30 control subjects with active lymph nodes were enrolled into our study. The baseline expression levels of lncRNAs HOTAIR, MALAT1, and PANDA in paraffin-embedded blocks of lymph nodes from DLBCL patients and controls were evaluated using reverse transcription quantitative real-time PCR (RTqPCR) technique.Results: The expression levels of HOTAIR and MALAT1 were increased while PANDA expression level was decreased in DLBCL patients when compared to controls and in R-CHOP-resistant patients when compared to responder ones. Also, HOTAIR, MALAT1, and PANDA baseline expression levels were significantly correlated with the different clinical parameters in this study. As diagnostic and prognostic tools, the results obtained from the ROC curve revealed that the PANDA baseline expression level was the best one as the diagnostic biomarker could differentiate DLBCL disease and the prognostic biomarker predicts R-CHOP resistance.Conclusion: In conclusion, the integrated approach reveals that lncRNAs HOTAIR and MALAT1 were upregulated, while lncRNA PANDA was downregulated in DLBCL patients compared with controls, and the three lncRNAs closely associated with clinical prognosis. This study warrants future studies in clinical trials for the treatment of R-CHOP-resistant DLBCL patients.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The PNH French Working Group Experience: Building a Strong Network of Cytometrists.

International journal of laboratory hematology Pub Date : 2025-02-25 DOI: 10.1111/ijlh.14449

Orianne Wagner-Ballon, Magali Le Garff-Tavernier, Rémi Lestestu, Bernard Drenou, Agathe Debliquis

{"title":"The PNH French Working Group Experience: Building a Strong Network of Cytometrists.","authors":"Orianne Wagner-Ballon, Magali Le Garff-Tavernier, Rémi Lestestu, Bernard Drenou, Agathe Debliquis","doi":"10.1111/ijlh.14449","DOIUrl":"https://doi.org/10.1111/ijlh.14449","url":null,"abstract":"Introduction: The PNH working group was created in 2010 to initiate a workshop on testing white blood cells to share international recommendations.Methods: Thirty-five French and Belgian laboratories equipped with 2- or 3-laser cytometers applied three different panels with or without FLAER reagent in 305 samples. This multicenter study demonstrated the interplatform applicability of setting harmonization and the benefits of using a harmonized gating method. A 10-4 limit of detection was achieved with harmonized multiparametric approaches in both six-color combinations, as well as a robust quantification of minor PNH clones.Results: Following this workshop, the group has developed a quality control scheme since 2013 to improve PNH diagnosis practices. This annual program includes two surveys, a virtual one and one based on fresh whole-blood sample analysis. Over the last 10 years, the regular participation of the French-speaking registered centers has demonstrated their strong commitment to our program, which offers various PNH clinical situations. Alongside, the conformity of the final reports provided by the participants has increased to 96%.Conclusion: In 2016, our PNH working group initiated a nationwide multicenter prospective observational study, collecting all PNH cases or GPI-deficient cells above 0.01% to monitor the long-term evolution of minor PNH clones < 1% and to further investigate the relevance of classifying type II and type III PNH cells in WBCs in clones > 1%. The strong network of cytometrists built led us to create in 2018 the French-speaking flow cytometry association in Hematology, namely CytHem, to harmonize the diagnostic practices in various hematological diseases.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143506659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and Validation of a User-Friendly Predictive Model Using Demographic and Complete Blood Count Data to Facilitate Early Diagnosis on Suspicion of Myeloproliferative Neoplasms. 利用人口统计学和全血细胞计数数据开发和验证用户友好型预测模型，以促进骨髓增生性肿瘤疑似患者的早期诊断。

International journal of laboratory hematology Pub Date : 2025-02-22 DOI: 10.1111/ijlh.14452

Lilan Jin, Lei Li, Yiyi Lu, Gang Cai, Lin Lin, Jiafei Lin

{"title":"Development and Validation of a User-Friendly Predictive Model Using Demographic and Complete Blood Count Data to Facilitate Early Diagnosis on Suspicion of Myeloproliferative Neoplasms.","authors":"Lilan Jin, Lei Li, Yiyi Lu, Gang Cai, Lin Lin, Jiafei Lin","doi":"10.1111/ijlh.14452","DOIUrl":"https://doi.org/10.1111/ijlh.14452","url":null,"abstract":"Objective: To develop a novel predictive model based on demographics and complete blood count (CBC) parameters to quickly identify suspicious features of myeloproliferative neoplasms (MPN), enabling prompt initiation of further investigations and referrals.Methods: 426 patients with elevated peripheral blood cell counts were referred to the Hematology Department of Ruijin Hospital from 2017 to 2023. Among them, 215 patients were diagnosed with MPN, while the remaining 211 patients formed the non-MPN group. The patients were randomly divided into a training cohort and a validation cohort. Demographic characteristics, CBC data, and other relevant laboratory information were collected. By univariable and multivariable logistic regression, significant indicators independently associated with MPN were identified and included in the nomogram. The model was evaluated by measuring the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA) curve.Results: Five indicators were identified as independently associated with MPN, including onset age, monocyte fraction, basophil fraction, red blood cell distribution width, and platelet count. The AUC values for the training and validation cohorts were 0.912 and 0.928, respectively. The calibration curves showed good agreement between the predicted risk by the nomogram and the actual outcomes. The DCA for the training and the validation datasets revealed net benefits of 0.9026 and 0.9303, respectively.Conclusion: We have developed and validated a prediction model for MPN based on demographics and CBC data. The model could assist general practitioners in quickly identifying patients with potential MPN and in initiating timely further investigations and referrals.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EBV-Positive Post-Transplant Diffuse Large B-Cell Lymphoma Following Allogeneic Hematopoietic Stem Cell Transplantation.

International journal of laboratory hematology Pub Date : 2025-02-20 DOI: 10.1111/ijlh.14450

Radu Chiriac, Marie Donzel

引用次数: 0

An Update on the Activities of the International Society for Laboratory Hematology, 2025. 2025 年国际血液化验协会活动的最新情况。

International journal of laboratory hematology Pub Date : 2025-02-20 DOI: 10.1111/ijlh.14446

John L Frater, Tracy I George

引用次数: 0

Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening.

International journal of laboratory hematology Pub Date : 2025-02-20 DOI: 10.1111/ijlh.14443

Mazen Assar, Henning Nilius, Natalie Kearn, Wilma Hopman, Michael Nagler, Maha Othman

{"title":"Thromboelastometry (ROTEM) Assessing Hypercoagulability in Patients Referred for Thrombophilia Screening.","authors":"Mazen Assar, Henning Nilius, Natalie Kearn, Wilma Hopman, Michael Nagler, Maha Othman","doi":"10.1111/ijlh.14443","DOIUrl":"https://doi.org/10.1111/ijlh.14443","url":null,"abstract":"Introduction: Thrombophilia, a blood coagulation disorder, poses risks of venous thromboembolism (VTE). Coagulation assays may not be sufficient to assess VTE risk and global assays such as Rotational Thromboelastometry (ROTEM) may add valuable information. We investigated ROTEM's capacity to detect hypercoagulability in patients undergoing thrombophilia screening, its potential impact on patient outcomes, and limitations.Methods: Comprehensive clinical, laboratory, genetic tests, and ROTEM (EXTEM and INTEM) were conducted for 356 patients referred for thrombophilia screening at an academic hospital outpatient unit. Hypercoagulability was identified as a shorter clot formation time (CFT), larger alpha angle (AA), and greater maximum clot firmness (MCF), and was compared in patients with and without VTE. Statistically this was analyzed using Mann-Whitney U and Chi-square tests with p < 0.05 considered significant.Results: Among 356 patients, 64.6% had previous VTE, with 76.9% experiencing one event, 14.3% recurrent (35.6% unprovoked, 64.4% provoked). 22.5% of patients were on anticoagulation. Those with VTE history exhibited significant alterations in EXTEM and INTEM parameters compared to those without (p < 0.001), showing decreased CFT and increased AA and MCF. However, receiver operating characteristic curves for these variables indicated that none were able to discriminate between those individuals with and without thromboembolic complications.Conclusion: ROTEM does not appear to be a strong discriminatory test. However, it can detect hypercoagulopathy in patients referred for thrombophilia screening. Abnormal ROTEM may indicate a higher risk for recurrence. However, this can only be determined in prospective cohort studies.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Activated Protein C Resistance Testing: An Update From Australasia/Asia-Pacific.

International journal of laboratory hematology Pub Date : 2025-02-19 DOI: 10.1111/ijlh.14447

Emmanuel J Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic

{"title":"Activated Protein C Resistance Testing: An Update From Australasia/Asia-Pacific.","authors":"Emmanuel J Favaloro, Sandya Arunachalam, Elysse Dean, Mahzuza Salwa, Monica Ahuja, Lynne Connelly, Kent Chapman, Ronny Vong, Leonardo Pasalic","doi":"10.1111/ijlh.14447","DOIUrl":"https://doi.org/10.1111/ijlh.14447","url":null,"abstract":"Introduction: Activated protein C resistance (APCR) represents a risk factor for thrombosis and is usually due to factor V Leiden (FVL). Clinicians may order either test (i.e., APCR or FVL) to help assess 'thrombophilia' in patients who present with thrombosis. APCR testing is usually achieved using clot-based assays, whereas FVL is assessed by genetic testing. There are advantages and disadvantages to either approach.Methods: We report updated findings for APCR testing in our geographic region, in part using recent data from the RCPAQAP, an international external quality assessment (EQA) program, with some 50-60 participants for APCR testing over the past decade. Data have been updated to cover the past 13 years (2010-2023 inclusive), with four samples assessed each year, but with a primary focus on new data from 2020 to 2023 inclusive. In addition, data for APCR testing over several years from four large tertiary-level hospital laboratories have been assessed following a recent change in instrumentation and haemostasis methods.Results: EQA data continue to show variable performance in both numerical values and their interpretation for APCR testing, with certain methods providing more consistently correct findings than others. In addition, participant interpretation of their own numerical values and transcription errors seem problematic. Finally, the change in recent laboratory testing has also evidenced local improvements.Conclusion: APCR assays and testing laboratories continue to show variability in performance, with two methods (Pefakit and Staclot) showing the best performance overall. Targeted education may be of benefit, as most of the errors appear to originate from a small proportion of laboratories.","PeriodicalId":94050,"journal":{"name":"International journal of laboratory hematology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143461206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0